What Revert does

REVERT is a cross-border clinical research project, not a commercial entity, led by the University of Cambridge's Brain Physics Laboratory (Department of Clinical Neurosciences, Division of Neurosurgery) and funded from October 2020 to June 2023 by the European Regional Development Fund (ERDF) via the Interreg France (Channel) England Programme. The project targets Normal Pressure Hydrocephalus (NPH), an under-diagnosed neurological condition often mislabelled as dementia despite being potentially reversible via shunt surgery. REVERT brings together three French academic institutions (University of Picardie Jules Verne, University of Artois, University of Caen Basse-Normandie), four university hospitals (Cambridge University Hospitals/Addenbrooke's, CHU Amiens-Picardie, CHU Brest, CHU Caen) and Cambridge-based health software firm Obex Technologies Ltd to build a clinical network of excellence across the Channel region.

The project's technical core combines two diagnostic modalities previously used in isolation: Phase-Contrast MRI (PC-MRI), pioneered by University of Picardie Jules Verne and CHU Amiens for non-invasive measurement of CSF and cranial blood flow, and computer-supported lumbar CSF infusion testing developed by Cambridge, which is embedded in UK NICE best-practice guidelines. REVERT also develops AI/deep-learning models to predict treatment responders, with the University of Artois (LML) applying neural networks to intracranial pressure and flow signals. Supporting software includes the ICM+ physiological monitoring platform (licensed to 200+ research centres globally), the Flow 2.0 PC-MRI post-processing tool (presented at ISMRM 2022), the HyPPo Hydrocephalus Management Portal built on Obex's Orion platform (which already connects 80+ UK hospitals and 140,000+ patient records), and an AI-driven motion-capture app for gait assessment funded by a €55,000 Interreg top-up.

REVERT has no commercial revenue stream. Its €3.6m total budget (€2.5m from ERDF plus €55,000 additional) finances multi-site clinical pathway implementation, one-stop multidisciplinary hydrocephalus clinics, regulatory and ethics approvals, scientific dissemination (ISMRM, Hydrocephalus Society, SBNS conferences, NPH Symposium), and the development of digital twins of the craniospinal system. Distribution runs through partner hospitals (NHS eRS, orion.net referrals at Addenbrooke's) and a publicly documented website (revertproject.org) with bilingual English/French content; the served "customer segment" is effectively NPH-suspected patients (predominantly over-65) and the clinicians treating them in the Interreg Channel area.

Name

Revert

Legal name

REVERT project (University of Cambridge)

Website

https://revertproject.org

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

REVERT is a cross-border clinical research project (University of Cambridge-led, ERDF/Interreg-funded, Oct 2020–Jun 2023, €3.6m budget) that combines PC-MRI and lumbar CSF infusion testing with AI/deep-learning tools to improve diagnosis of Normal Pressure Hydrocephalus across UK and French partner hospitals.

Ownership category

akta.pro rank

Product category

Neurological Diagnostics Research

NAICS

Scientific Research and Development Services (5417)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Normal pressure hydrocephalus diagnosis
• Hydrocephalus clinical research
• CSF dynamics monitoring
• Neurosurgery diagnostics
• Dementia care research

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. European Regional Development Fund (ERDF) via Interreg: REVERT is funded from October 2020 until June 2023 with a total budget of €3.6m, of which €2.5m is being funded by the ERDF (European Regional Development Fund) via the Interreg France (Channel) England Programme. Additional funding of EUR 55,000 was approved for motion capture app development.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

REVERT is a cross-border clinical research project that develops and implements innovative diagnostic tools for Normal Pressure Hydrocephalus (NPH). It combines Phase-Contrast MRI (PC-MRI) and lumbar cerebrospinal fluid (CSF) infusion testing with AI/deep learning models to predict treatment responders, and operates a multidisciplinary hydrocephalus clinic and web-based Hydrocephalus Management Portal (HyPPo) across UK and French partner hospitals.

Product overview

REVERT (Reversible Dementia Project) is a cross-border research initiative funded by the European Regional Development Fund via Interreg France (Channel) England Programme. The project does not offer commercial products for sale but develops and implements clinical tools and software for Normal Pressure Hydrocephalus (NPH) diagnosis. Key components include: the Hydrocephalus Management Portal (HyPPo) web platform being developed by Obex Technologies; ICM+ brain monitoring software from University of Cambridge for physiological data collection and analysis; Flow 2.0 post-processing software for PC-MRI; and a motion capture app for AI-powered gait assessment. The clinical infrastructure includes a multidisciplinary clinic at Cambridge University Hospitals, PC-MRI diagnostics, lumbar CSF infusion testing services, and the UK Shunt Registry hosted on the Orion platform. The project combines PC-MRI flow measurements with infusion test pressure recordings, uses AI/neural networks for treatment prediction, and is building digital models of craniospinal fluid dynamics.

Differentiator

Problem solved

Functional benefit

Products and services

• Multidisciplinary Hydrocephalus Clinic One-stop NPH and CSF disorder assessment clinic at Addenbrooke's Hospital combining neurosurgical consultation, clinical neuropsychology, specialist physiotherapy, advanced nurse specialist review, and advanced diagnostics. For patients with suspected normal pressure hydrocephalus in the East of England and beyond.
• Lumbar CSF Infusion Testing

Quantifiable outcome

• Shunt testing saves Addenbrooke's hospital an estimated £1m per year by avoiding unnecessary shunt revision surgery
• +2 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core.

• University of CambridgecoreStrategic or Co-development Partner · 1 October 2020Lead Partner of the REVERT project. Brain Physics Laboratory focuses on studying cerebrospinal fluid (CSF) dynamics and multimodal brain monitoring. Scientists Dr Peter Smielewski, Prof. Marek Czosnyka, and Dr Zofia Czosnyka are world-leading experts with 60,000+ citations. Developed ICM+ software licensed to 200+ clinical research centres worldwide. Oversees the entire REVERT project.
• University of Picardie Jules VernecoreStrategic or Co-development Partner · 1 October 2020Multidisciplinary university with 30,000 students, 35 research units and ~800 researchers. CHIMERE laboratory and BIOFLOW Image branch developing digital models for fluid interaction in the cranial system. Led by Dr Olivier Balédent. Pioneered PC-MRI analysis of CSF and blood flows for diagnosing hydrocephalus. Building a digital model dedicated to interaction of fluids in the cranial system.
• University of ArtoiscoreStrategic or Co-development Partner · 1 October 2020Laboratoire de Mathématiques de Lens (LML) pioneering work on Artificial Intelligence with track record in geometry, algebra, analysis and mathematical physics. Team led by Dr Yaël Frégier. Focuses on mathematical/deep learning models for prediction of NPH treatment responders. Received additional EUR 55,000 funding for motion capture app development.
• Cambridge University Hospitals NHS Foundation TrustcoreStrategic or Co-development Partner · 1 October 2020Leading hydrocephalus centre in the UK combining clinical assessment with neuroradiology and CSF dynamics studies. Evaluating feasibility of combined infusion tests and PC MRI in daily clinical practice. Hosts the project's clinical lead (Mr Alexis Joannides). About 400 patients with CSF dynamics problems seen annually, with ~120 potentially presenting with NPH symptoms.
• CHU Amiens-Picardie (University Hospital of Amiens)coreStrategic or Co-development Partner · 1 October 2020One of two public university health establishments and tertiary centre of Hauts-de-France region. Teams of biophysicists, neurosurgeons and radiologists with internationally recognised experience in hydrocephalus management. Implementing phase contrast MRI-based diagnostics in other partner hospitals. ~200 patients per year seen for suspected NPH.
• CHU Brest (University Hospital of Brest)coreStrategic or Co-development Partner · 1 October 2020Neurosurgery Department manages cranial and spinal neurosurgical pathologies, especially hydrocephalus, for Brittany region. Department has 42 beds and 8 intensive care beds. Neuroradiology Unit has MRI. Implementing pressure and flow diagnostics procedures in hydrocephalus clinic and recruiting patients.
• CHU Caen (University Hospital of Caen)coreStrategic or Co-development Partner · 1 October 2020Neurosurgery Department provides care for all cranial and spinal neurosurgical pathologies of Lower Normandy region and surrounding areas. Team committed to providing quality care and up-to-date standards. Department has 50 hospital beds. Affiliated with University of Caen Basse-Normandie.
• Obex Technologies LtdcoreTechnology or Integration · 1 October 2020Healthcare software company based in Cambridge UK with established track record in developing secure databases for long-term surveillance of neurological disease. Established Orion cloud-based healthcare platform in 2012, now maintaining seven UK national registries. Over 80 UK hospitals participate with data from 140,000+ patients. Leading clinical informatics work package including development of Hydrocephalus Management Portal.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medtronic plc: Global medical device leader and the dominant hydrocephalus shunt manufacturer. Medtronic competes with REVERT at the treatment end of the NPH pathway (shunt implantation) that REVERT's diagnostic tools aim to make more accurate.
• Integra LifeSciences: Through its Codman Specialty Surgical division, Integra manufactures hydrocephalus shunts and neurosurgery devices. It is a broad incumbent in the same NPH/neurosurgery value chain that REVERT's diagnostics feed into.
• B. Braun Melsungen AG: Owner of Aesculap and Miethke, B. Braun is a major supplier of hydrocephalus valves and neurosurgery systems. It operates broadly across the neurosurgery device category that REVERT's diagnostic pathway ultimately supports.
• Brainlab AG: Vendor of surgical planning, navigation and AI software for neurosurgery. Brainlab's broad neurosurgery software portfolio partially overlaps with REVERT's HyPPo/Orion-based patient pathway management capability.
• ClearPoint Neuro, Inc. Provider of MRI-guided neurosurgery navigation and drug delivery platforms. ClearPoint operates in the same neurosurgery decision-support space that REVERT's PC-MRI-based diagnostic pathway and HyPPo portal serve.

Emerging players

• NovaSignal Corporation: Emerging player combining neurosonography with AI for cerebral blood flow assessment. NovaSignal's AI-on-flow-imaging approach is thematically aligned with REVERT's PC-MRI + neural network work on CSF and blood flow analysis.
• HeadSense Medical Ltd. Emerging player developing non-invasive intracranial pressure monitoring technology. HeadSense overlaps with REVERT's ICP and CSF dynamics focus area with a differentiated, less invasive approach.

Direct peers

• Sophysa SA: Specialist in hydrocephalus shunts and intracranial pressure monitoring devices. Sophysa overlaps directly with REVERT's lumbar infusion testing and CSF pressure measurement capabilities in NPH diagnosis and shunt assessment.
• Möller Medical GmbH: Neurosurgery device specialist offering external CSF drainage systems and ICP monitoring accessories. Möller Medical addresses the same hydrocephalus/ICP measurement workflow that REVERT's diagnostic platform supports.
• Spiegelberg GmbH: Manufacturer of intracranial pressure monitoring devices and accessories used in neurosurgery. Spiegelberg competes directly with the University of Cambridge's ICM+ infusion testing technology central to REVERT's protocol.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/REVERT_Interreg
• LinkedInlinkedin.com/company/revert-dementia-project

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revert